Back to results
US 2015/0031735 A1Published application
Solid forms of a transthyretin dissociation inhibitor
AssigneePfizer Inc.
InventorsRichard Frederic Labaudiniere, MICHAEL HENRY O'Neill
Life of this patent
Estimating the term…
Abstract
The present invention relates to solid forms of the N-methyl-D-glucamine (meglumine) salt of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one solid form and to the therapeutic or prophylactic use of such solid forms and compositions.
Claims8
A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole meglumine, wherein said crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2θ) of 10.7±0.2, 11.8±0.2, and 13.3±0.2.
4-9. (canceled)
Dependencies are inferred from the claim text.